Publications by authors named "Yishan Ye"

Article Synopsis
  • * A study analyzed 284 MDS patients, finding no significant survival benefits from cytoreductive treatment before HSCT compared to those receiving best supportive care (BSC).
  • * Ultimately, whether patients underwent cytoreduction or BSC, their post-transplant outcomes were similar, indicating that this treatment approach does not improve prognosis for TP53-mutated MDS patients.
View Article and Find Full Text PDF

Background: Post-transplant lymphoproliferative disorder (PTLD) is a rare but highly fatal complication occurring after allogeneic hematopoietic cell transplantation (allo-HCT) or solid organ transplantation (SOT). Unlike SOT, PTLD after allo-HCT usually originates from the donor and is rarely accompanied by a loss of donor chimerism.

Case Summary: We report a case of Epstein-Barr virus positive PTLD manifesting as diffuse large B-cell lymphoma (DLBCL) with significantly decreased T-cell chimerism early after allo-HCT.

View Article and Find Full Text PDF
Article Synopsis
  • * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
  • * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
View Article and Find Full Text PDF

Purpose Of Review: The past two decades have witnessed an impressive expansion in the treatment landscape of multiple myeloma, leading to significant improvements in progression-free; as well as overall survival. However, almost all patients still experience multiple relapses during their disease course, with biological and cytogenetic heterogeneity affecting response to subsequent treatments. The purpose of this review is to provide a historical background regarding the role of alkylating agents and an updated data regarding the use of peptide-drug conjugates such as melflufen for patients with multiple myeloma.

View Article and Find Full Text PDF

Objective: The early identification and diagnosis of transplant-associated thrombotic microangiopathy (TA-TMA) are essential yet difficult in patients underwent hematopoietic stem cell transplantation (HSCT). To develop an evidence-based, nurse-leading early warning model for TA-TMA, and implement the healthcare quality review and improvement project.

Methods: This study was a mixed-methods, before-and-after study.

View Article and Find Full Text PDF

Membranous nephropathy (MN) is a rare complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT). MN patients may develop nephrotic syndrome or even kidney failure, which greatly affects their quality of life and prognosis. However, current knowledge regarding MN after allo-HSCT is limited.

View Article and Find Full Text PDF

Additional chromosomal abnormalities(ACAs) at diagnosis are associated with inferior prognosis in chronic myeloid leukemia. However, the prognostic significance of ACAs in adult patients with Philadelphia Chromosome Positive acute lymphoblastic leukemia (Ph + ALL) receiving TKI-targeted drugs and allogeneic hematopoietic stem cell transplantation(HSCT) is unknown. One hundred thirty-six adult patients with Ph + ALL were included in the study and retrospectively analysed, evaluating the effect of ACAs on outcomes of transplantation.

View Article and Find Full Text PDF

Background: Cancer-targeted T-cell receptor T (TCR-T) cells hold promise in treating cancers such as hematological malignancies and breast cancers. However, approaches to obtain cancer-reactive TCR-T cells have been unsuccessful.

Methods: Here, we developed a novel strategy to screen for cancer-targeted TCR-T cells using a special humanized mouse model with person-specific immune fingerprints.

View Article and Find Full Text PDF
Article Synopsis
  • Human herpesvirus 6 (HHV6) encephalitis is a serious condition that can develop in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a low incidence of around 1.48%.
  • A study identified that younger patients (under 30) and those with low NK cell counts shortly after transplantation are at a higher risk for developing this condition.
  • Patients with HHV6 encephalitis experience significantly worse outcomes, including higher rates of serious complications and lower survival rates compared to those without the encephalitis.
View Article and Find Full Text PDF

Background: Both humoral and cell-mediated immunity of the patient affected by multiple myeloma (MM) are impaired; thus, infection is the main cause of the onset of symptoms and death caused by MM. Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bortezomib-induced peripheral neuropathy (PN) remains a significant side effect that has led to its discontinuation in some patients.

View Article and Find Full Text PDF

De novo anti-HLA donor-specific antibodies (DSAs) were rarely reported in stem cell transplantation patients. We present a case of 39-year-old acute myelogenous leukaemia patient who developed de novo DSAs only 16 days after transplantation with the highest mean fluorescence intensity (MFI) of 7406.23, which were associated with poor graft function (PGF).

View Article and Find Full Text PDF
Article Synopsis
  • Scientists did a study to see if a special transplant method called haplo-cord HCT is better for people with a type of blood cancer called acute myeloid leukemia (AML).
  • They found that patients who got haplo-cord HCT had a better chance of surviving after 3 years compared to those who had the regular haplo-HCT.
  • Also, haplo-cord HCT helped patients recover faster and had good results without causing too many side effects.
View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for patients with core-binding factor mutated (CBF) acute myeloid leukemia (AML) who have achieved second complete remission (CR2), though 20% may relapse after the procedure.
  • A study analyzed outcomes from 865 CBF AML patients undergoing allo-HCT with different donor types (haploidentical, matched siblings, and matched unrelated donors) across 227 centers, revealing that haploidentical transplants were linked to a lower relapse incidence compared to the other donor types.
  • CBF-AML patients with the inv(16) mutation had better outcomes regarding relapse, overall survival, and graft-versus-host disease-free survival
View Article and Find Full Text PDF

The psychological side effects of granulocyte colony-stimulating factor mobilization in related donors of allogeneic hematopoietic cell transplantation (allo-HCT) and impacts of psychological/physical side effects on harvest outcomes remain largely unknown. We prospectively analyzed 349 consecutive related peripheral blood stem cell (PBSC) donors for allo-HCT at the First Affiliated Hospital, Zhejiang University, School of Medicine from March 2021 to August 2023. Higher baseline peripheral blood white blood cell counts (p = 0.

View Article and Find Full Text PDF

Microplastics (MPs) are contaminants ubiquitously found in the global biosphere that enter the body through inhalation or ingestion, posing significant risks to human health. Recent studies emerge that MPs are present in the bone marrow and damage the hematopoietic system. However, it remains largely elusive about the specific mechanisms by which MPs affect hematopoietic stem cells (HSCs) and their clinical relevance in HSC transplantation (HSCT).

View Article and Find Full Text PDF

Keratoconus (KC), a leading cause of vision impairment, has an unclear aetiology. This study used Mendelian randomization (MR) to explore the causal links between various factors (smoking, asthma, Down syndrome, inflammatory bowel disease, atopic dermatitis, and serum 25-hydroxyvitamin D levels) and KC. A two-sample MR design, grounded in genome-wide association study (GWAS) summary statistics, was adopted using data from FinnGen, UK Biobank, and other GWAS-related articles.

View Article and Find Full Text PDF

Objectives: This study aimed to characterize the clinical characteristics, outcomes, and risk factors for coronavirus disease 2019 (COVID-19) in 492 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) during the Omicron wave.

Methods: Data were retrospectively collected from patient charts and the electronic medical record systems at the First Affiliated Hospital of Zhejiang University School of Medicine between December 2022 and January 2023.

Results: The median follow-up period of the entire cohort was 62 days.

View Article and Find Full Text PDF

rearrangement (-r) in patients with acute myeloid leukemia (AML) is associated with poor outcomes; the prognostic factors after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear. We investigated 364 adults with AML who underwent allo-HSCT between April 2016 and May 2022, and 45 had -r among them. Propensity score analysis with 1:1 matching and the nearest neighbor matching method identified 42 patients in -r and non--r cohorts, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • - The study examined the cellular makeup of peripheral blood grafts in patients undergoing ATG-based haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from 2016 to 2021, focusing on factors influencing survival rates.
  • - Results showed that a higher dose of graft CD8 T cells significantly improved overall and disease-free survival, with additional findings linking older patient/donor ages and disease risk to survival outcomes.
  • - A predictive model was developed to assess survival risks based on graft CD8 T-cell dose, donor age, and disease risk index, highlighting the importance of younger donors and higher lymphocyte percentages for better patient outcomes.
View Article and Find Full Text PDF

Background: Although chimeric antigen receptor-modified T cells (CAR T) cell therapy has been widely reported in improving the outcomes of B-cell acute lymphoblastic leukemia (B-ALL), less research about the feasibility and safety of donor-derived CAR T after allogeneic hematopoietic stem cell transplantation (allo-HSCT) was reported.

Methods: This phase 1 clinical trial aims to evaluate safety and efficacy of donor-derived anti-CD19 CAR T cells (GC007g) in B-ALL patients who relapsed after allo-HSCT. This trial is registered with ClinicalTrials.

View Article and Find Full Text PDF

Donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used in preventing post-transplant relapse. We conducted this study to compare the superiority of prophylactic modified DLI (pro-DLI) and preemptive modified DLI (pre-DLI) in patients with high-risk relapse features acute leukemia. Pro-DLI was performed in 95 patients, whereas the pre-DLI cohort included 176 patients.

View Article and Find Full Text PDF